KYTX Key Statistics, Chart & Performance
The current stock price of KYTX is 7.68 USD. In the past month the price increased by 7.11%. In the past year, price increased by 33.1%.
KYTX Latest News, Press Relases and Analysis
KYTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About KYTX
Company Profile
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Company Info
KYVERNA THERAPEUTICS INC
5980 Horton Street, Suite 550
Emeryville CALIFORNIA US
Employees: 129
Phone: 15106268331
KYVERNA THERAPEUTICS INC / KYTX FAQ
What does KYTX do?
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Can you provide the latest stock price for KYVERNA THERAPEUTICS INC?
The current stock price of KYTX is 7.68 USD. The price increased by 3.92% in the last trading session.
What is the dividend status of KYVERNA THERAPEUTICS INC?
KYTX does not pay a dividend.
What is the ChartMill rating of KYVERNA THERAPEUTICS INC stock?
KYTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for KYTX stock?
12 analysts have analysed KYTX and the average price target is 24.48 USD. This implies a price increase of 218.75% is expected in the next year compared to the current price of 7.68.
What is KYVERNA THERAPEUTICS INC worth?
KYVERNA THERAPEUTICS INC (KYTX) has a market capitalization of 332.16M USD. This makes KYTX a Small Cap stock.
What is the Short Interest ratio of KYVERNA THERAPEUTICS INC (KYTX) stock?
The outstanding short interest for KYVERNA THERAPEUTICS INC (KYTX) is 7.09% of its float.
KYTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KYTX. When comparing the yearly performance of all stocks, KYTX is one of the better performing stocks in the market, outperforming 95.54% of all stocks.
KYTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KYTX. While KYTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
KYTX Financial Highlights
Over the last trailing twelve months KYTX reported a non-GAAP Earnings per Share(EPS) of -3.73. The EPS increased by 87.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.02% | ||
| ROE | -105.95% | ||
| Debt/Equity | 0 |
KYTX Forecast & Estimates
12 analysts have analysed KYTX and the average price target is 24.48 USD. This implies a price increase of 218.75% is expected in the next year compared to the current price of 7.68.